Skip to main content
. 2009 Jan;20(1):68–77. doi: 10.1681/ASN.2008010036

Figure 5.

Figure 5.

Imatinib reduces liver and lung injury in TSLP-Tg mice. Representative liver and lung sections stained with H & E of a control TSLP-Tg mouse and an imatinib-treated TSLP-Tg mouse receiving 4 wk of treatment beginning at age day 90. Imatinib dramatically reduces portal inflammatory cell infiltrates and lung infiltrates.